Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
Innovent Biologics announced that seven of its innovative products are now part of the 2026 National Reimbursement Drug List. These products include Mazdutide and PECONDLE. The biopharmaceutical company researches and manufactures drugs for several major diseases. These include metabolic, autoimmune, ophthalmic, and oncology conditions.
PALO ALTO, Calif. and SUZHOU, China, Nov. 14, 2026 /PRNewswire/ — Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced that seven innovative products of Innovent were successfully included in the updated […]